Report quantifies China's state-backed market support via buybacks and share purchases
Report shows 1,051 Chinese firms planned over 220 billion yuan in buybacks; state entities added >60 billion yuan in shareholdings.
Global stock markets: index moves, earnings, analyst targets and the policy and rate backdrop driving them.
Report shows 1,051 Chinese firms planned over 220 billion yuan in buybacks; state entities added >60 billion yuan in shareholdings.
Dell reports fiscal Q2 after Tuesday's close; options imply an 11% swing, with a $52 straddle, and investors watching AI orders and margins.
Major US stock indices ended lower except for the Nasdaq 100, which eked out a small gain.
The FTC plans to sue Amazon for allegedly manipulating ad auction prices, and Amazon stock dropped over 3% on the news.
Strive bought 1,800 BTC for $143 million, becoming the fifth-largest public bitcoin treasury. Its stock rose 9%.
European shares closed mixed as oil prices surged and yields rose. UK FTSE 100 and Italy FTSE MIB gained.
GameStop shares rose 4% after paying $358.4 million to stop a convertible note exchange that could have diluted shareholders. The fix retires only a third of…
U.S. stocks opened lower on Monday, with the S&P 500 and Nasdaq falling below their 100-hour moving averages as yields and oil prices rose.
Longsys seeks up to $800M in a Hong Kong IPO, pricing shares at a 45% discount to its Shenzhen stock.
U.S. stock futures edged lower as markets weigh Fed Chair Warsh's remarks and look ahead to key economic data.
AIFO Funding launches AI Trading Coach that analyzes market, trader behavior, and account risk for prop traders.
Nvidia's 8.7% post-earnings gain brightened sentiment, but Marvell's 10.3% drop showed selectivity remains key in Q3 earnings.
Nasdaq futures rebound from 29,300 but need to clear 29,745-29,815 to confirm a bullish reversal.
John Ternus takes over as Apple CEO on Sept. 1; past tech handoffs show first-year returns from -38% to +76%. AAPL closed near $320.
Biotechs developing hair loss treatments attract investor interest, with no new drug approved since the 1990s.